Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses

Detalhes bibliográficos
Autor(a) principal: Tamez Perez,Hector Eloy
Data de Publicação: 2012
Outros Autores: Gómez de Ossio,María Dolores, Quintanilla Flores,Dania Lizet, Hernández Coria,Mayra Ivonne, Tamez Peña,Alejandra Lorena, Cuz Pérez,Gissén Jazmín, Proskauer Peña,Stephanie Lissette
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista da Associação Médica Brasileira (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302012000100025
Resumo: OBJECTIVE: Methylprednisolone pulses are used in a variety of disease conditions, both for acute and chronic therapy. Although well tolerated, they increase glucose levels in both non-diabetic and diabetic patients. They may also be considered a significant risk for acute metabolic alterations. The purpose of this report is to determine the metabolic changes in blood glucose levels in non-diabetic patients receiving methylprednisolone pulses and identify the presence of predictive factors for its development. METHODS: Observational, prospective study in 50 non-diabetic patients receiving 1 g intravenous methylprednisolone pulses for three consecutive days as an indication for diverse autoimmune disorders. Demographic, anthropometric, and metabolic variables were analyzed, and glucose, insulin and C-peptide levels after each steroid pulse were identified. Different variables and the magnitude of hyperglycemia were analyzed using Pearson's correlation. RESULTS: 50 patients were included, predominantly women (66%, n = 33). The average age was 41 ± 14 years with a BMI of 26 ± 3 kg/m². Baseline glucose was 83 ± 10 mg/dL. After each steroid pulse, glucose increased to 140 ± 28, 160 ± 38 and 183 ± 44, respectively (p < 0.001). C-peptide and insulin concentrations increased significantly (p < 0.001). The prevalence of fasting hyperglycemia after each pulse was 68%, 94% and 98%, respectively. We found no correlation between the magnitude of hyperglycemia and the studied variables. CONCLUSION: Methylprednisolone pulses produced significant increases in fasting glucose in most patients without diabetes. Further studies are needed to define its role in long-term consequences.
id AMB-1_7f50be6f6f04c8cabd41d2a1c1fff5b9
oai_identifier_str oai:scielo:S0104-42302012000100025
network_acronym_str AMB-1
network_name_str Revista da Associação Médica Brasileira (Online)
repository_id_str
spelling Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulsesMethylprednisolonediabetes mellitushyperglycemiaOBJECTIVE: Methylprednisolone pulses are used in a variety of disease conditions, both for acute and chronic therapy. Although well tolerated, they increase glucose levels in both non-diabetic and diabetic patients. They may also be considered a significant risk for acute metabolic alterations. The purpose of this report is to determine the metabolic changes in blood glucose levels in non-diabetic patients receiving methylprednisolone pulses and identify the presence of predictive factors for its development. METHODS: Observational, prospective study in 50 non-diabetic patients receiving 1 g intravenous methylprednisolone pulses for three consecutive days as an indication for diverse autoimmune disorders. Demographic, anthropometric, and metabolic variables were analyzed, and glucose, insulin and C-peptide levels after each steroid pulse were identified. Different variables and the magnitude of hyperglycemia were analyzed using Pearson's correlation. RESULTS: 50 patients were included, predominantly women (66%, n = 33). The average age was 41 ± 14 years with a BMI of 26 ± 3 kg/m². Baseline glucose was 83 ± 10 mg/dL. After each steroid pulse, glucose increased to 140 ± 28, 160 ± 38 and 183 ± 44, respectively (p < 0.001). C-peptide and insulin concentrations increased significantly (p < 0.001). The prevalence of fasting hyperglycemia after each pulse was 68%, 94% and 98%, respectively. We found no correlation between the magnitude of hyperglycemia and the studied variables. CONCLUSION: Methylprednisolone pulses produced significant increases in fasting glucose in most patients without diabetes. Further studies are needed to define its role in long-term consequences.Associação Médica Brasileira2012-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302012000100025Revista da Associação Médica Brasileira v.58 n.1 2012reponame:Revista da Associação Médica Brasileira (Online)instname:Associação Médica Brasileira (AMB)instacron:AMB10.1590/S0104-42302012000100025info:eu-repo/semantics/openAccessTamez Perez,Hector EloyGómez de Ossio,María DoloresQuintanilla Flores,Dania LizetHernández Coria,Mayra IvonneTamez Peña,Alejandra LorenaCuz Pérez,Gissén JazmínProskauer Peña,Stephanie Lissetteeng2012-02-28T00:00:00Zoai:scielo:S0104-42302012000100025Revistahttps://ramb.amb.org.br/ultimas-edicoes/#https://old.scielo.br/oai/scielo-oai.php||ramb@amb.org.br1806-92820104-4230opendoar:2012-02-28T00:00Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)false
dc.title.none.fl_str_mv Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses
title Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses
spellingShingle Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses
Tamez Perez,Hector Eloy
Methylprednisolone
diabetes mellitus
hyperglycemia
title_short Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses
title_full Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses
title_fullStr Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses
title_full_unstemmed Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses
title_sort Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses
author Tamez Perez,Hector Eloy
author_facet Tamez Perez,Hector Eloy
Gómez de Ossio,María Dolores
Quintanilla Flores,Dania Lizet
Hernández Coria,Mayra Ivonne
Tamez Peña,Alejandra Lorena
Cuz Pérez,Gissén Jazmín
Proskauer Peña,Stephanie Lissette
author_role author
author2 Gómez de Ossio,María Dolores
Quintanilla Flores,Dania Lizet
Hernández Coria,Mayra Ivonne
Tamez Peña,Alejandra Lorena
Cuz Pérez,Gissén Jazmín
Proskauer Peña,Stephanie Lissette
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Tamez Perez,Hector Eloy
Gómez de Ossio,María Dolores
Quintanilla Flores,Dania Lizet
Hernández Coria,Mayra Ivonne
Tamez Peña,Alejandra Lorena
Cuz Pérez,Gissén Jazmín
Proskauer Peña,Stephanie Lissette
dc.subject.por.fl_str_mv Methylprednisolone
diabetes mellitus
hyperglycemia
topic Methylprednisolone
diabetes mellitus
hyperglycemia
description OBJECTIVE: Methylprednisolone pulses are used in a variety of disease conditions, both for acute and chronic therapy. Although well tolerated, they increase glucose levels in both non-diabetic and diabetic patients. They may also be considered a significant risk for acute metabolic alterations. The purpose of this report is to determine the metabolic changes in blood glucose levels in non-diabetic patients receiving methylprednisolone pulses and identify the presence of predictive factors for its development. METHODS: Observational, prospective study in 50 non-diabetic patients receiving 1 g intravenous methylprednisolone pulses for three consecutive days as an indication for diverse autoimmune disorders. Demographic, anthropometric, and metabolic variables were analyzed, and glucose, insulin and C-peptide levels after each steroid pulse were identified. Different variables and the magnitude of hyperglycemia were analyzed using Pearson's correlation. RESULTS: 50 patients were included, predominantly women (66%, n = 33). The average age was 41 ± 14 years with a BMI of 26 ± 3 kg/m². Baseline glucose was 83 ± 10 mg/dL. After each steroid pulse, glucose increased to 140 ± 28, 160 ± 38 and 183 ± 44, respectively (p < 0.001). C-peptide and insulin concentrations increased significantly (p < 0.001). The prevalence of fasting hyperglycemia after each pulse was 68%, 94% and 98%, respectively. We found no correlation between the magnitude of hyperglycemia and the studied variables. CONCLUSION: Methylprednisolone pulses produced significant increases in fasting glucose in most patients without diabetes. Further studies are needed to define its role in long-term consequences.
publishDate 2012
dc.date.none.fl_str_mv 2012-02-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302012000100025
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302012000100025
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0104-42302012000100025
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Médica Brasileira
publisher.none.fl_str_mv Associação Médica Brasileira
dc.source.none.fl_str_mv Revista da Associação Médica Brasileira v.58 n.1 2012
reponame:Revista da Associação Médica Brasileira (Online)
instname:Associação Médica Brasileira (AMB)
instacron:AMB
instname_str Associação Médica Brasileira (AMB)
instacron_str AMB
institution AMB
reponame_str Revista da Associação Médica Brasileira (Online)
collection Revista da Associação Médica Brasileira (Online)
repository.name.fl_str_mv Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)
repository.mail.fl_str_mv ||ramb@amb.org.br
_version_ 1754212830268096512